ScripThe pharmaceutical industry in Europe has criticized the Council of the EU’s adoption of a package of legislative reforms for medicines, claiming that the continent’s innovation-unfriendly environment
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D
In VivoAs major pharmaceutical companies continue investing heavily in immunology –with Sanofi’s recent $9.1bn acquisition of Blueprint Medicines underscoring the sector’s strategic importance – San Franci
ScripIt has been a good week for Bayer’s oncology franchise, securing a third indication for its prostate cancer blockbuster Nubeqa and presenting positive data on its investigational menopause drug elinza